The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate | Strategic Alliance Partners

April 19, 2024

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

November 23, 2023

Omid Hamid, MD, director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai, discusses the rationale for a phase 1 trial of fianlimab plus cemiplimab in patients with advanced melanoma who have received prior adjuvant PD-1 inhibitors.

September 12, 2023

Inderjit Mehmi, MD, medical oncologist, discusses the rationale for investigating the combination of fianlimab and cemiplimab in patients who have advanced melanoma with poor-risk features

August 17, 2023

Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.

July 24, 2023

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

June 13, 2023

Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.

September 21, 2022

The combination of fianlimab and cemiplimab demonstrated clinically meaningful activity in patients with advanced melanoma who were naïve to anti–PD-1/PD-L1 therapy.

August 17, 2022

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

September 30, 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

October 12, 2020

In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.

September 17, 2020

In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.

August 24, 2020

Omid Hamid, MD, discusses the utility of tumor mutational burden as a biomarker for response to immunotherapy in patients with melanoma.

December 01, 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

November 03, 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the effectiveness of immunotherapy in adolescent and young adult (AYA) patients with melanoma.

October 30, 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma.

March 05, 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

February 14, 2017

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

December 30, 2016

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.

December 14, 2015

Omid Hamid, MD, Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic, discusses a recent trial investigating the combination of vemurafenib and atezolizumab in melanoma in patients with previously untreated BRAF-positive unresectable or metastatic melanoma.

May 01, 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.